Why Is HIV Drug Giant Gilead Stock Trading Lower Today?
Gilead Sciences Inc GILD said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or…#nsclc #trop2 #gild
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Lung Cancer | Non-Small Cell Lung Cancer | Study | Taxotere